Sheryar Siddiq
Tue, November 25, 2025 astatine 7:39 AM CST 2 min read
Atai Beckley NV (NASDAQ:ATAI) reported coagulated findings from the open-label hold survey successful its Phase 2b objective proceedings for BPL-003. The survey recovered that administering a 12 mg dose of BPL-003 8 weeks aft the archetypal dose resulted successful accelerated antidepressant effects that lasted up to 8 weeks.
In addition, the study covered Atai Beckley NV (NASDAQ:ATAI) shareholders approving the acquisition of Beckley Psytech Limited and the company’s anticipated redomiciliation successful Delaware. In that context, the institution besides filed a connection for the resale of up to 5.3 cardinal shares successful transportation with its acquisition of Beckley Psytech.
Atai Beckley NV (NASDAQ:ATAI), headquartered successful the Netherlands, is simply a clinical-stage biopharmaceutical institution processing innovative treatments for intelligence wellness disorders, including depression, anxiety, and substance usage disorders.
While we admit the imaginable of ATAI arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.
READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.
Disclosure: None. This nonfiction is primitively published at Insider Monkey.

5 days ago
8



.png)

English (CA) ·
English (US) ·
Spanish (MX) ·